Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to determine the progression free survival in
patients with metastatic pancreatic cancer and in patients with locally advanced unresectable
non-metastatic pancreatic cancer treated with a dose-attenuated modification of folinic acid,
fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX). Secondary endpoints included:
determine objective response rate according to RECIST; determine overall survival; evaluate
toxicity; determine rate of resection in locally advanced unresectable stratum; correlate
time to progression, objective response, and overall survival with early changes in glucose
metabolism using [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) scanning.